Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03337724
Recruitment Status : Recruiting
First Posted : November 9, 2017
Last Update Posted : February 27, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 22, 2021
  Estimated Study Completion Date : December 22, 2021